Core Viewpoint - Jimin Health (603222) announced a share buyback of 2,005,500 shares, representing 0.3819% of the company's total share capital as of September 30, 2025 [1] Summary by Category - **Company Actions** - The company has executed a share buyback program, acquiring a total of 2,005,500 shares [1] - The buyback accounts for 0.3819% of the total share capital [1]

Core Viewpoint - Jimin Health (603222.SH) announced a share buyback program, indicating a strategic move to enhance shareholder value through repurchasing shares in the market [1] Summary by Categories Share Buyback Details - The company has repurchased a total of 2.0055 million shares, which represents 0.3819% of its total share capital [1] - The highest purchase price was 6.13 CNY per share, while the lowest was 5.87 CNY per share [1] - The total amount spent on the buyback was 12.089 million CNY, excluding transaction fees [1]

证券代码：603222 证券简称：济民健康 公告编号：2025-049 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 关于以集中竞价交易方式回购股份的进展公告 重要内容提示： | 回购方案首次披露日 | 2025/3/29 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 个月 12 | | 预计回购金额 | 10,000万元~20,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | 累计已回购股数 | 200.55万股 | | 累计已回购股数占总股本比例 | 0.38% | | 累计已回购金额 | 1,208.90万元 | | 实际回购价格区间 | 5.87元/股~6.13元/股 | 一、回购股份的基本情况 济民健康管理股份有限公司(以下简称"公司")于 2025 年 3 月 28 日召开第 五届董事会第十七次会议，审议通过了《关于以集中竞价交易方式回购股份方案 的议案》，同意公司使用自有资金及金融 ...

Core Points - The company approved a share repurchase plan with a maximum price of 10 CNY per share and a total fund amount of 100 million to 200 million CNY, valid for up to 12 months from the board's approval date [1] - As of September 30, 2025, the company has repurchased a total of 2.0055 million shares, accounting for 0.3819% of the total share capital, with a maximum purchase price of 6.13 CNY per share and a minimum price of 5.87 CNY per share, totaling 12.089 million CNY spent (excluding transaction fees) [1] - No repurchase was executed in September 2025, and the company will repurchase shares as per regulations and disclose information in a timely manner [1]

Core Viewpoint - Jimin Health (603222.SH) is transitioning from a focus on large-volume infusion, medical devices, and healthcare services to becoming an innovative pharmaceutical company, marked by the acceptance of a clinical trial application for DB006 on September 26, 2025 [1]. Group 1: Company Transition - Jimin Health's subsidiary, Boao International Hospital, received a clinical trial acceptance notice for DB006, a oncolytic adenovirus injection, indicating the company's first step towards becoming an innovative drug enterprise [1]. - The registration classification of DB006 is as a Class 1 therapeutic biological product, signifying a significant shift in Jimin Health's business model since its establishment in 1996 [1]. Group 2: Market Context - In 2020, China reported 4.57 million new cancer cases and 3 million cancer deaths, with high incidence and mortality rates for liver, stomach, esophageal, and cervical cancers [1]. - Breast cancer has the highest incidence rate, followed by lung and colorectal cancers, with lung cancer remaining the leading cause of cancer-related deaths [1]. Group 3: Oncolytic Virus Therapy - Oncolytic virus therapy is recognized as a promising new type of cancer treatment, characterized by high efficiency in killing tumor cells, specificity, safety, low side effects, and cost-effectiveness [2]. - Currently, five oncolytic virus drugs have been approved globally, with approximately seven oncolytic virus drugs in clinical trials in China, most in Phase I/II [2]. Group 4: Product Details - DB006 is designed for the treatment of advanced malignant solid tumors, utilizing genetic engineering to enhance tumor-specific replication and selectively infect tumor cells [2]. - In preclinical models, DB006 demonstrated over 70% tumor suppression in colon cancer models and complete tumor remission in non-small cell lung cancer models [2]. Group 5: Financial Performance - In the first half of 2025, Jimin Health reported total revenue of 366 million yuan, a decrease of 21.3% year-on-year, with a net loss attributable to shareholders of 52.7 million yuan [3]. - The company attributed its losses to reduced revenue and profit from medical devices due to U.S. tariff policies and inventory write-downs related to specific products [3].

Core Insights - The medical device sector experienced a slight increase of 0.39% on September 29, with Tianzhihang leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Medical Device Sector Performance - Tianzhihang (688277) saw a closing price of 18.47, with a rise of 7.70% and a trading volume of 172,400 shares, amounting to a transaction value of 315 million yuan [1] - Jimin Health (603222) closed at 11.30, up 5.51%, with a trading volume of 494,600 shares and a transaction value of 556 million yuan [1] - Dongxing Medical (301290) closed at 29.32, increasing by 4.86%, with a trading volume of 99,500 shares and a transaction value of 29.67 million yuan [1] - Other notable performers included Sainuo Medical (688108) with a 4.82% increase and a closing price of 27.83, and Tianchen Medical (688013) with a 3.89% increase, closing at 59.52 [1] Capital Flow Analysis - The medical device sector saw a net inflow of 85.63 million yuan from institutional investors, while retail investors contributed a net inflow of 46.52 million yuan [2] - However, speculative funds experienced a net outflow of 132 million yuan [2] Individual Stock Capital Flow - Sainuo Medical (688108) had a net inflow of 111 million yuan from institutional investors, but a net outflow of 68.66 million yuan from speculative funds [3] - Mairui Medical (300760) also saw a significant net inflow of 107 million yuan from institutional investors, with a net outflow of 76.49 million yuan from speculative funds [3] - Jimin Health (603222) had a net inflow of 53.49 million yuan from institutional investors, while speculative funds saw a net outflow of 43.40 million yuan [3]

申请人：海南济民博鳌国际医院有限公司、广州达博生物制品有限公司 受理号：CXSL2500840 证券代码：603222 证券简称：济民健康 公告编号：2025-048 济民健康管理股份有限公司 关于控股子公司药品临床试验申请取得受理通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 博鳌国际医院 DB006 溶瘤腺病毒注射液已正式获得国家药品监督管理局 药品审评中心受理 I 期临床研究申请。根据我国药品注册相关的法律法规要求， 临床试验申请获得受理后，自受理之日起 60 日内，未收到国家药品监督管理局 药品审评中心否定或质疑意见，方能按照已提交的方案开展临床试验，期间结果 具有一定的不确定性。生物药品具有高科技、高风险、高附加值的特点。药品的 前期研发以及产品从研制、临床试验、上市审批到产业化生产的周期长、环节多， 容易受多种不确定因素的影响。公司将按照有关规定，对项目进展情况及时履行 信息披露义务，敬请广大投资者谨慎决策，注意防范投资风险。 济民健康管理股份有限公司（以下简称"公司"）控股子公司 ...

Core Viewpoint - Jimin Health (603222) announced that its subsidiary, Hainan Jimin Boao International Hospital Co., Ltd., received the acceptance notice for the clinical trial application of DB006 on September 26, 2025, from the National Medical Products Administration's Center for Drug Evaluation (CDE) [1] Company Summary - The DB006 oncolytic adenovirus injection is a gene therapy drug aimed at treating advanced malignant solid tumors [1]

Core Viewpoint - Jimin Health (603222.SH) announced that its subsidiary, Hainan Jimin Boao International Hospital, received a clinical trial acceptance notice from the National Medical Products Administration for the DB006 oncolytic adenovirus injection, indicating progress in its gene therapy development for advanced malignant solid tumors [1] Group 1 - The Boao International Hospital's DB006 oncolytic adenovirus injection is designed for the treatment of advanced malignant solid tumors [1] - The product utilizes genetic engineering to modify oncolytic viruses for selective infection of tumor cells and enhanced tumor-specific replication capabilities [1] - The therapy incorporates multiple anti-tumor and immune-regulating genes to target and kill tumors through various pathways [1]

Core Viewpoint - Jimin Health (603222.SH) announced that its subsidiary, Hainan Jimin Boao International Hospital, received a clinical trial acceptance notice from the National Medical Products Administration (NMPA) for the DB006 oncolytic adenovirus injection, aimed at treating advanced malignant solid tumors [1] Group 1: Company Developments - The Boao International Hospital's DB006 oncolytic adenovirus injection is a gene therapy drug designed for advanced malignant solid tumors [1] - The product utilizes genetic engineering to modify oncolytic viruses for selective infection of tumor cells and enhanced tumor-specific replication capabilities [1] - The drug incorporates multiple anti-tumor and immune-regulating genes to target and kill tumors through various mechanisms [1]